Article Information
- Received May 5, 2003
- Revision received June 10, 2003
- Accepted June 17, 2003
- First published August 6, 2003.
- Version of record published August 6, 2003.
Author Information
Author contributions
Disclosures
- Received May 5, 2003.
- Revision received June 10, 2003.
- Accepted June 17, 2003.
This work was supported by National Institutes of Health (NIH) Grant NS28840 (N.R.) and National Multiple Sclerosis Society (NMSS) Grant RG3229-A-4 (N.R.). R.M. was supported by NIH and NMSS. T.R. was supported in part by Department of Defense Grant on Neurofibromatosis (NF000023), and M.B. was supported by National Institute of Neurological Disorders and Stroke Grant 5 T32 N707453. R.M. is a member of The Cancer Institute of New Jersey. We thank Robert Miller (Case Western) for initial observations of NF1 spinal cord cells. The farnesyltransferase inhibitor used was a kind gift from Jackson Gibbs and Nancy Kohl (Merck Research Laboratories). We thank Yuan Huang for help with timed dissections, Annie Stammen and Jason Bowersock for genotyping embryos, and Johanna Hadley, Brenda Meinhardt, and Sylvie Ebner for maintenance of NF1 (J.H. and B.M.) and MBP [shiverer] (S.E.) mouse colonies. The rat 401 (nestin) and 5A5 (E-NCAM) antibodies developed by S. Hockfield (rat 401), T. M. Jessel, and J. Dodd (5A5) were obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the National Institute of Child Health and Human Development, and maintained by The University of Iowa Department of Biological Sciences.
Correspondence should be addressed to Nancy Ratner, Department of Cell Biology, Neurobiology, and Anatomy, University of Cincinnati College of Medicine, 3125 Eden Avenue, Cincinnati, OH 45267-0521. E-mail: nancy.ratner{at}uc.edu.
Copyright © 2003 Society for Neuroscience 0270-6474/03/237207-11$15.00/0
Online Impact